NCT03961230 is a Phase 2 clinical trial of Jueyin granules in Psoriasis Vulgaris, sponsored by Shanghai Yueyang Integrated Medicine Hospital.

Who is sponsoring NCT03961230?

NCT03961230 is sponsored by Shanghai Yueyang Integrated Medicine Hospital.

What drugs are being tested in NCT03961230?

Interventions in NCT03961230: Jueyin granules, Jueyin Granules Placebo.

What condition does NCT03961230 study?

NCT03961230 studies Psoriasis Vulgaris.

Is NCT03961230 still recruiting?

NCT03961230 is currently status unknown. Last updated 23 May 2019.

Last reviewed 2019-05-23 · How we verify

NCT03961230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome

Status unknown Phase 2 Last updated 23 May 2019

What this trial tests

Phase 2 trial testing Jueyin granules in Psoriasis Vulgaris in 196 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai Yueyang Integrated Medicine Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	196
Start date	1 June 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	4 locations across China

Drugs / interventions tested

Jueyin granules — full drug profile →
Jueyin Granules Placebo

Conditions studied

Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →

Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Who can join

Adults 18 to 65, any sex, with Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We designed this study as a multicenter, randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of psoriasis with blood stasis syndrome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials.
Luo Y, Chen J, Kuai L, Zhang Y, et al · · 2020 · cited 19× · PMID 33551804 · DOI 10.3389/fphar.2020.599433
Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial.
Li S, Zhang C, Zhang HY, Zhou M, et al · · 2020 · cited 3× · PMID 32351609 · DOI 10.1155/2020/8942301

Verify or expand the search:

Other trials of Jueyin granules

Trials testing the same drug.

NCT03941431 — Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine · Phase 2 · unknown

Other recruiting trials for Psoriasis Vulgaris

Currently open trials in the same condition.

NCT07426120 — Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III · Phase 3 · recruiting
NCT07320872 — Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris · recruiting
NCT06398106 — Proactive TDM Versus Standard Use of Biologics in Psoriasis · Phase 4 · recruiting
NCT05185258 — Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study · Phase 4 · active not recruiting
NCT04950218 — Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis · recruiting

Other Shanghai Yueyang Integrated Medicine Hospital trials

Trials by the same sponsor.

NCT07434076 — Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional · not yet recruiting
NCT07351448 — Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine · not yet recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT06922565 — Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis · NA · not yet recruiting
NCT06790940 — Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03961230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yueyang Integrated Medicine Hospital
Last refreshed: 23 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03961230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing